Betta Pharmaceuticals (300558.SZ): Drug Registration Application for Ensartinib Hydrochloride Capsules as Postoperative Adjuvant Therapy Accepted

Stock News11-26

Betta Pharmaceuticals Co., Ltd. (300558.SZ) announced that it has received the "Acceptance Notice" (Acceptance No.: CXHS2500142, CXHS2500143) issued by the National Medical Products Administration (NMPA). The company's marketing authorization application for Ensartinib Hydrochloride Capsules (brand name: Bemnax®) has been accepted by the NMPA. The drug is intended for use as postoperative adjuvant therapy in patients with anaplastic lymphoma kinase (ALK)-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have undergone surgical resection, with or without adjuvant chemotherapy as determined by their physician.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1123336276?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-26 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123336276","market":"us","top_or_hot":-1,"title":"Betta Pharmaceuticals (300558.SZ): Drug Registration Application for Ensartinib Hydrochloride Capsules as Postoperative Adjuvant Therapy Accepted","media":"Stock News","content":"<p>Betta Pharmaceuticals Co., Ltd. (300558.SZ) announced that it has received the \"Acceptance Notice\" (Acceptance No.: CXHS2500142, CXHS2500143) issued by the National Medical Products Administration (NMPA). The company's marketing authorization application for Ensartinib Hydrochloride Capsules (brand name: Bemnax®) has been accepted by the NMPA. The drug is intended for use as postoperative adjuvant therapy in patients with anaplastic lymphoma kinase (ALK)-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have undergone surgical resection, with or without adjuvant chemotherapy as determined by their physician.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Betta Pharmaceuticals (300558.SZ): Drug Registration Application for Ensartinib Hydrochloride Capsules as Postoperative Adjuvant Therapy Accepted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBetta Pharmaceuticals (300558.SZ): Drug Registration Application for Ensartinib Hydrochloride Capsules as Postoperative Adjuvant Therapy Accepted\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-26 12:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Betta Pharmaceuticals Co., Ltd. (300558.SZ) announced that it has received the \"Acceptance Notice\" (Acceptance No.: CXHS2500142, CXHS2500143) issued by the National Medical Products Administration (NMPA). The company's marketing authorization application for Ensartinib Hydrochloride Capsules (brand name: Bemnax®) has been accepted by the NMPA. The drug is intended for use as postoperative adjuvant therapy in patients with anaplastic lymphoma kinase (ALK)-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have undergone surgical resection, with or without adjuvant chemotherapy as determined by their physician.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"91287","symbol_name":"贝达药业股份有限公司（临时代码）","start_time":0,"source_url":"","article_id":"1123336276","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123336276","pubTimestamp":1764130331,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Betta Pharmaceuticals Co., Ltd. (300558.SZ) announced that it has received the \"Acceptance Notice\" (Acceptance No.: CXHS2500142, CXHS2500143) issued by the National Medical Products Administration...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"91287":"贝达药业股份有限公司（临时代码）","300558":"贝达药业","BK0239":"医药制造","BK0060":"抗癌"},"translate_title":"贝达药业（300558.SZ）：盐酸恩沙替尼胶囊术后辅助治疗药品注册申请获受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"91287":1,"300558":1},"content_text":"Betta Pharmaceuticals Co., Ltd. (300558.SZ) announced that it has received the \"Acceptance Notice\" (Acceptance No.: CXHS2500142, CXHS2500143) issued by the National Medical Products Administration (NMPA). The company's marketing authorization application for Ensartinib Hydrochloride Capsules (brand name: Bemnax®) has been accepted by the NMPA. The drug is intended for use as postoperative adjuvant therapy in patients with anaplastic lymphoma kinase (ALK)-positive stage IB to IIIB non-small cell lung cancer (NSCLC) who have undergone surgical resection, with or without adjuvant chemotherapy as determined by their physician.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1123336276","isCrawlerRequest":true}